FDA Form 483 — Milla Pharmaceuticals, Inc. (March 12, 2026) — 1 Citations

Observation 1 — Written procedures have not been developed for the of post marketing adverse drug

Written procedures have not been developed for the of post marketing adverse drug experiences. Specifically, procedures for vendor qualification and auditing have not been followed concerning the PV vendor, initially contracted in 11/2021, with no initial qualification, annual reassessment, or contract- required audit each 2 years. ͘ ͘ ͘ ͘ ͘ ͘ ͘ PAGE 1 of 1 PAGES Sharon L Matson Investigator Signed By: SHARON L. MATSON -S Date Signed: 03-13-2026 08:50:17 -- 1 of 2 --   The observations of objectionable conditions and practices listed on the front of this form are reported: 1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or 2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration. Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides: "Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in hi A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.